Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience

Guedea, Ferrán; Ferrer, Montserrat; Pera, J.; Aguiló, F; Boladeras, A.; Suárez, José Francisco; Cunillera, Oriol; Ferrer, F.; Pardo, Yolanda; Martinez, E.; Ventura, Montse

doi:10.1007/s12094-009-0387-x

Cited by 20 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,33,46 In an RCT in low-risk patients, results were consistent with the above observational studies at 1 year, but these differences for PROs were not sustained at 5 years.…”

Section: 46supporting

confidence: 64%

Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer

Rodrigues

Yao²,

Loblaw³

et al. 2013

CUAJ

View full text Add to dashboard Cite

Objective: The Genitourinary Cancer Disease Site Group (GU DSG) and Cancer Care Ontario's Program in Evidence-Based Care (PEBC) in Ontario, Canada developed a guideline on low-dose rate brachytherapy (LDR-BT) in patients with early-stage low-grade prostate cancer in 2001. The current updated guideline focuses on the research questions regarding the effect of LDR-BT alone, the effect of LDR-BT with external beam radiation therapy (EBRT) and the selection of an isotope. Methods: This guideline was developed by using the methods of the Practice Guidelines Development Cycle and the core methodology was a systematic review. MEDLINE and EMBASE (from January 1996 to October 2011), the Cochrane Library, main guideline websites, and main annual meeting abstract websites specific for genitourinary diseases were searched. Internal and external reviews of the draft guideline were conducted. Results: The draft guideline was developed according to a total of 10 systematic reviews and 55 full text articles that met the preplanned study selection criteria. The quality of evidence was low to moderate. The final report reflects integration of the feedback obtained through the internal review (two oncologists and a methodologist) and external review (five target reviewers and 48 professional consultation reviewers) process, with final approval given by the GU DSG and the PEBC. Conclusion:The main recommendations are: (1) For patients with newly diagnosed low-risk or intermediate-risk prostate cancer who require or choose active treatment, LDR-BT alone is a treatment option as an alternative to EBRT alone or RP alone; and (2) I-125 and Pd-103 are each reasonable isotope options.

show abstract

“…22,33,46 In an RCT in low-risk patients, results were consistent with the above observational studies at 1 year, but these differences for PROs were not sustained at 5 years.…”

Section: 46supporting

confidence: 64%

Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer

Rodrigues

Yao²,

Loblaw³

et al. 2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Acutely after prostatectomy, 80% to 90% of patients report difficulty with erections (9,10), but this proportion decreases to approximately 60% by 2 years (9,19,21). After radiation, erectile dysfunction increases with time and is reported by 50% to 60% of external beam radiation patients and 20% to 50% of brachytherapy patients at 2 years (9,10,13,19,22). Those who received radiation alone (without androgen deprivation therapy) had better outcomes (9).…”

Section: Brief Communicationmentioning

confidence: 99%

Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials

Chen¹,

Chang²,

Vetter³

et al. 2014

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee convened four working groups to recommend core sets of patient-reported outcomes to be routinely incorporated in clinical trials. The Prostate Cancer Working Group included physicians, researchers, and a patient advocate. The group's process included 1) a systematic literature review to determine the prevalence and severity of symptoms, 2) a multistakeholder meeting sponsored by the NCI to review the evidence and build consensus, and 3) a postmeeting expert panel synthesis of findings to finalize recommendations. Five domains were recommended for localized prostate cancer: urinary incontinence, urinary obstruction and irritation, bowel-related symptoms, sexual dysfunction, and hormonal symptoms. Four domains were recommended for advanced prostate cancer: pain, fatigue, mental well-being, and physical well-being. Additional domains for consideration include decisional regret, satisfaction with care, and anxiety related to prostate cancer. These recommendations have been endorsed by the NCI for implementation.

show abstract

“…Many recent studies have examined quality of life following treatment and have shown that the choice of treatment has a considerable impact (Table 4). [70][71][72][73][74][75] A controlled study examined the negative effects three years after treatment for localized prostate cancer and reported worse urinary function associated with surgery; whereas bowel function was poorest with radiotherapy. 70 Sexual dysfunction was similar between groups.…”

Section: Comparative Health-related Quality Of Life Estimates Followimentioning

confidence: 99%

“…One study examined the QOL after radical prostatectomy, radiotherapy or brachytherapy and demonstrated QOL varies as a function of treatment. 71 A general health-related QOL questionnaire was used (Medical Outcomes Study Short-Form 36 ), composed of physical (PCS) and mental (MCS) component scores, and a specific health-related quality of life (HRQOL) questionnaire with domains of urinary, sexual and incontinence. At 2 years these three QOL measures were worse with prostatectomy.…”

Section: Comparative Health-related Quality Of Life Estimates Followimentioning

confidence: 99%

Is radical prostatectomy the best option for localized prostate cancer? Current opinion and research

Shelley¹,

Mason²

2010

OAS

View full text Add to dashboard Cite

Open radical prostatectomy is an effective treatment for prostate cancer with a 5-year biochemical recurrence-free survival rate of about 90% for localized disease. For men with organ confined disease, the 10 year disease-specific survival rate approximates 95% following retropubic prostatectomy. Attempts to improve survival rates by combining androgen deprivation therapy with radical prostatectomy have been unsuccessful. Erectile dysfunction and urinary incontinence are common complications following open radical prostatectomy. In an attempt to reduce morbidity, laparoscopic approaches have been developed with reported 8-year cancer control rates of about 70%. Robotic laparoscopic approaches yield a trifecta rate of achieving continence, potency and being prostate-specific antigen recurrence-free at 2 years of 74%. Comparative studies do not provide evidence that one surgical approach is superior. Few randomized trials have compared surgery with the other primary therapies for prostate cancer. A Scandinavian randomized study has reported that the metastatic rate and overall mortality are significantly better with surgery compared to watchful waiting. However, there are no published data from randomized trials comparing surgery with radiotherapy (external beam or brachytherapy), active surveillance or minimally invasive procedures. There are ongoing randomized trials comparing surgery with radiotherapy, brachytherapy, and active surveillance, but until these are published, there is no conclusive evidence that surgery is the best primary option for localized or locally advanced prostate cancer.

show abstract

Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience

Cited by 20 publications

References 40 publications

Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer

Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer

Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials

Is radical prostatectomy the best option for localized prostate cancer? Current opinion and research

Contact Info

Product

Resources

About